Cumberland Pharmaceuticals (CPIX) Reports Q2 EPS of $0.04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Cumberland Pharmaceuticals Reports Second Quarter 2016 Financial Results
August 2, 2016 4:05 PM EDTNASHVILLE, Tenn., Aug. 2, 2016 /PRNewswire/ --Â Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced second quarter 2016 financial results with Net Revenues of $7.4 million and Adjusted Earnings of $0.7 million or $0.04 per share.
As of June 30, 2016, the Company had approximately $88 million in Total Assets including $50 million in cash and marketable securities. Total Liabilities were approximately $14 million and Total Shareholder's Equity was just over $74 million. Cumberland also had approximately $43 million in tax net... More
